Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1991 Apr;84(1):103–108.

Serum levels of tumour necrosis factor-alpha and interleukin-1 beta during leprosy reactional states.

E N Sarno 1, G E Grau 1, L M Vieira 1, J A Nery 1
PMCID: PMC1535359  PMID: 2015700

Abstract

The possible role of cytokines in leprosy reactions was investigated by analysing the levels of tumour necrosis factor (TNF) and interleukin-1 (IL-1) in serum samples from 39 leprosy patients, 22 of them presenting either type I (upgrading) or type II (ENL) reactions. Fifty per cent of the patients showed elevated concentrations of TNF and IL-1 in at least one of the serum samples tested. This included all four patients undergoing type I reversal reaction and nine (50%) of the ENL patients studied. Concentrations of TNF above 1000 pg/ml were found in four patients with ENL. Development of erythema multiforme in these ENL patients represented an aggravating factor and all four patients suffering from this type of lesion demonstrated increased serum TNF levels. All BT patients tested presented elevated IL-1 levels, while only half of them presented elevated levels of TNF. No correlation was found between any particular systemic symptoms and the levels of TNF and IL-1. These results suggest that TNF and IL-1 may be implicated in leprosy reactions, either acting directly or in synergism with other cytokines.

Full text

PDF
103

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Arend W. P., Welgus H. G., Thompson R. C., Eisenberg S. P. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest. 1990 May;85(5):1694–1697. doi: 10.1172/JCI114622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Beutler B., Cerami A. Cachectin: more than a tumor necrosis factor. N Engl J Med. 1987 Feb 12;316(7):379–385. doi: 10.1056/NEJM198702123160705. [DOI] [PubMed] [Google Scholar]
  3. Billingham M. E. Cytokines as inflammatory mediators. Br Med Bull. 1987 Apr;43(2):350–370. doi: 10.1093/oxfordjournals.bmb.a072187. [DOI] [PubMed] [Google Scholar]
  4. Blanchard D. K., Djeu J. Y., Klein T. W., Friedman H., Stewart W. E., 2nd Protective effects of tumor necrosis factor in experimental Legionella pneumophila infections of mice via activation of PMN function. J Leukoc Biol. 1988 May;43(5):429–435. doi: 10.1002/jlb.43.5.429. [DOI] [PubMed] [Google Scholar]
  5. Debets J. M., Ruers T. J., van der Linden M. P., van der Linden C. J., Buurman W. A. Inhibitory effect of corticosteroids on the secretion of tumour necrosis factor (TNF) by monocytes is dependent on the stimulus inducing TNF synthesis. Clin Exp Immunol. 1989 Nov;78(2):224–229. [PMC free article] [PubMed] [Google Scholar]
  6. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990 Jan 25;265(3):1531–1536. [PubMed] [Google Scholar]
  7. Gad S. M., Shannon E. J., Krotoski W. A., Hastings R. C. Thalidomide induces imbalances in T-lymphocyte sub-populations in the circulating blood of healthy males. Lepr Rev. 1985 Mar;56(1):35–39. doi: 10.5935/0305-7518.19850006. [DOI] [PubMed] [Google Scholar]
  8. Girardin E., Grau G. E., Dayer J. M., Roux-Lombard P., Lambert P. H. Tumor necrosis factor and interleukin-1 in the serum of children with severe infectious purpura. N Engl J Med. 1988 Aug 18;319(7):397–400. doi: 10.1056/NEJM198808183190703. [DOI] [PubMed] [Google Scholar]
  9. Godal T. Immunological aspects of leprosy--present status. Prog Allergy. 1978;25:211–242. [PubMed] [Google Scholar]
  10. Grau G. E., Fajardo L. F., Piguet P. F., Allet B., Lambert P. H., Vassalli P. Tumor necrosis factor (cachectin) as an essential mediator in murine cerebral malaria. Science. 1987 Sep 4;237(4819):1210–1212. doi: 10.1126/science.3306918. [DOI] [PubMed] [Google Scholar]
  11. Grau G. E., Piguet P. F., Vassalli P., Lambert P. H. Involvement of tumour necrosis factor and other cytokines in immune-mediated vascular pathology. Int Arch Allergy Appl Immunol. 1989;88(1-2):34–39. doi: 10.1159/000234744. [DOI] [PubMed] [Google Scholar]
  12. Grau G. E., Roux-Lombard P., Gysler C., Lambert C., Lambert P. H., Dayer J. M., Guillevin L. Serum cytokine changes in systemic vasculitis. Immunology. 1989 Oct;68(2):196–198. [PMC free article] [PubMed] [Google Scholar]
  13. Grau G. E., Taylor T. E., Molyneux M. E., Wirima J. J., Vassalli P., Hommel M., Lambert P. H. Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med. 1989 Jun 15;320(24):1586–1591. doi: 10.1056/NEJM198906153202404. [DOI] [PubMed] [Google Scholar]
  14. Kapp A., Zeck-Kapp G., Blohm D. Human tumor necrosis factor is a potent activator of the oxidative metabolism in human polymorphonuclear neutrophilic granulocytes: comparison with human lymphotoxin. J Invest Dermatol. 1989 Mar;92(3):348–354. doi: 10.1111/1523-1747.ep12277174. [DOI] [PubMed] [Google Scholar]
  15. Kasahara K., Kobayashi K., Shikama Y., Yoneya I., Kaga S., Hashimoto M., Odagiri T., Soejima K., Ide H., Takahashi T. The role of monokines in granuloma formation in mice: the ability of interleukin 1 and tumor necrosis factor-alpha to induce lung granulomas. Clin Immunol Immunopathol. 1989 Jun;51(3):419–425. doi: 10.1016/0090-1229(89)90040-8. [DOI] [PubMed] [Google Scholar]
  16. Laal S., Mishra R. S., Nath I. Type 1 reactions in leprosy--heterogeneity in T-cell functions related to the background leprosy type. Int J Lepr Other Mycobact Dis. 1987 Sep;55(3):481–493. [PubMed] [Google Scholar]
  17. Larrick J. W. Native interleukin 1 inhibitors. Immunol Today. 1989 Feb;10(2):61–66. doi: 10.1016/0167-5699(89)90308-3. [DOI] [PubMed] [Google Scholar]
  18. Libby P., Ordovas J. M., Auger K. R., Robbins A. H., Birinyi L. K., Dinarello C. A. Endotoxin and tumor necrosis factor induce interleukin-1 gene expression in adult human vascular endothelial cells. Am J Pathol. 1986 Aug;124(2):179–185. [PMC free article] [PubMed] [Google Scholar]
  19. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin 1. J Exp Med. 1986 Jun 1;163(6):1363–1375. doi: 10.1084/jem.163.6.1363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Nawroth P. P., Stern D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med. 1986 Mar 1;163(3):740–745. doi: 10.1084/jem.163.3.740. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Oliff A. The role of tumor necrosis factor (cachectin) in cachexia. Cell. 1988 Jul 15;54(2):141–142. doi: 10.1016/0092-8674(88)90543-0. [DOI] [PubMed] [Google Scholar]
  22. Piguet P. F., Grau G. E., Allet B., Vassalli P. Tumor necrosis factor/cachectin is an effector of skin and gut lesions of the acute phase of graft-vs.-host disease. J Exp Med. 1987 Nov 1;166(5):1280–1289. doi: 10.1084/jem.166.5.1280. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rao T. D., Rao P. R. Enhanced cell-mediated immune responses in erythema nodosum leprosum reactions of leprosy. Int J Lepr Other Mycobact Dis. 1987 Mar;55(1):36–41. [PubMed] [Google Scholar]
  24. Ridley D. S., Jopling W. H. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis. 1966 Jul-Sep;34(3):255–273. [PubMed] [Google Scholar]
  25. Sariban E., Imamura K., Luebbers R., Kufe D. Transcriptional and posttranscriptional regulation of tumor necrosis factor gene expression in human monocytes. J Clin Invest. 1988 May;81(5):1506–1510. doi: 10.1172/JCI113482. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Scuderi P., Sterling K. E., Lam K. S., Finley P. R., Ryan K. J., Ray C. G., Petersen E., Slymen D. J., Salmon S. E. Raised serum levels of tumour necrosis factor in parasitic infections. Lancet. 1986 Dec 13;2(8520):1364–1365. doi: 10.1016/s0140-6736(86)92007-6. [DOI] [PubMed] [Google Scholar]
  27. Seckinger P., Zhang J. H., Hauptmann B., Dayer J. M. Characterization of a tumor necrosis factor alpha (TNF-alpha) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci U S A. 1990 Jul;87(13):5188–5192. doi: 10.1073/pnas.87.13.5188. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Sehgal V. N. Reactions in leprosy. Clinical aspects. Int J Dermatol. 1987 Jun;26(5):278–285. doi: 10.1111/j.1365-4362.1987.tb00188.x. [DOI] [PubMed] [Google Scholar]
  29. Selmaj K., Raine C. S. Tumor necrosis factor mediates myelin damage in organotypic cultures of nervous tissue. Ann N Y Acad Sci. 1988;540:568–570. doi: 10.1111/j.1749-6632.1988.tb27175.x. [DOI] [PubMed] [Google Scholar]
  30. Silva C. L., Foss N. T. Tumor necrosis factor in leprosy patients. J Infect Dis. 1989 Apr;159(4):787–790. doi: 10.1093/infdis/159.4.787. [DOI] [PubMed] [Google Scholar]
  31. Vázquez-Botet M., Sánchez J. L. Erythema nodosum leprosum. Int J Dermatol. 1987 Sep;26(7):436–437. doi: 10.1111/j.1365-4362.1987.tb00585.x. [DOI] [PubMed] [Google Scholar]
  32. Waage A., Brandtzaeg P., Halstensen A., Kierulf P., Espevik T. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med. 1989 Jan 1;169(1):333–338. doi: 10.1084/jem.169.1.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Waage A., Halstensen A., Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet. 1987 Feb 14;1(8529):355–357. doi: 10.1016/s0140-6736(87)91728-4. [DOI] [PubMed] [Google Scholar]
  34. Watson S., Bullock W., Nelson K., Schauf V., Gelber R., Jacobson R. Interleukin 1 production by peripheral blood mononuclear cells from leprosy patients. Infect Immun. 1984 Sep;45(3):787–789. doi: 10.1128/iai.45.3.787-789.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES